Divamics Secures Strategic Investment from Suzhou Angel Fund to Accelerate Innovative Drug R&D and Translation

VCBeat learned第一时间 that in August 2025, Divamics Inc. (Divamics, hereinafter referred to as "Divamics") announced that it had obtainedSuzhou Angel FOFStrategic Investment. Following the acquisition in May 2025Yuansheng Venture CapitalAfter the leading investment, Divamics' Series A financing process has reached a new level.

DivamicsDivamics Inc. has built a unique multi-scale molecular dynamics simulation platform and an innovative early drug discovery AI decision-making platform, aiming to more accurately understand the dynamic interactions and mechanisms of drug molecules and targets, rationally design drugs, predict efficacy and drug-likeness, and break through traditional drug discovery bottlenecks. It provides a Hits-to-PCC integrated R&D platform for various types of drug research and development, including small molecules, peptides, and large molecules. The company has been awarded the Suzhou Industrial Park Technology Leadership Program, the Suzhou Municipal Gusu Talent Leadership Program, and recognized as a National High-tech Enterprise. Its core technology has been recommended by Professor Roald Hoffmann, a Nobel Prize winner in Chemistry. The company's headquarters is located in Suzhou, with a computing center in Beijing and BD cooperation centers in Singapore and Japan. Currently, it has collaborated with over 50 domestic and international biopharmaceutical companies.8More than 0 new drug R&D pipelines.

In terms of financing history,Divamics has completed multiple rounds of financing:

• In July 2022, received angel round investment from Suzhou Angel FOF;

• In May 2023, it completed the PRE-A round of financing led by Fosun Health Capital, with follow-up investment from Sino-Singapore Capital.

• In May 2025, it received funding led by YuanSheng Ventures.

• In August 2025, Suzhou Angel FOF made a strategic investment.

In recent years, global investment in new drug research and development has continued to rise. According to statistics from Evaluate Pharma, an authoritative data and forecasting institution in the global pharmaceutical industry, global pharmaceutical R&D investment reached nearly $288 billion in 2024. By 2030, R&D spending in this industry is expected to reach approximately $340 billion. However, despite the vast market prospects, most AI pharmaceutical companies in China still have pipelines in the research and development stage, with the industry rapidly transitioning from technical validation to clinical implementation.

As market investments continue to rise and the industry rapidly transitions, Divamics focuses on utilizing multi-scale molecular dynamics combined with self-innovated AI algorithms to build a new generation of artificial intelligence drug discovery platform. Its core technologyDIVAMICS Kinetics Platform and BIOTRAJECTORY DatabaseBased on AI-driven multi-scale molecular dynamics, it can simulate dynamic changes in protein structures and drug target binding modes ranging from tens of nanoseconds to milliseconds. This enables highly flexible target modeling, druggability analysis of targets, and structural screening, design, and optimization for small molecules, PROTACs, molecular glues, peptides, and other drug types. This technological breakthrough overcomes the limitation of traditional artificial intelligence, which can only analyze static protein images, allowing for more precise identification of binding sites. Combined with virtual screening, it significantly improves the hit rate of new drug molecules. This technology is expected to shorten the new drug development cycle by 2 to 3 years and reduce costs by approximately 30% to 50%.

In terms of scientific research achievements,Divamics has obtained the first U.S. patent authorization for its AI drug design algorithm and built the world's first kinetic trajectory database, promoting the integration of big data in research and development with patents and clinical information. In February this year, the company’s collaborative achievements with Peking University School of Pharmaceutical Sciences, Wuhan University of Technology, and other universities were successively published in sub-journals of international academic journals such as Cell and Nature, providing academic validation for "AI-assisted drug discovery."

In terms of commercialization,Currently, the company has served more than 50 pharmaceutical industry clients both in China and internationally, including 10 listed companies, advancing over 80 new drug R&D pipelines in collaboration, and achieving more than 10 cooperative pipeline compound patent filings, with several already entering Phase III clinical trials.

The addition of new strategic investors,Further validating Divamics' technical approach and industrialization potential in the AI pharmaceuticals field. In the future, the company will continue to deepen its core platform capabilities, expand into more collaborative scenarios, and accelerate the research, development, and translation of innovative drugs.

Suzhou Angel FOF (full name "Suzhou Angel Investment Guidance Fund") is a government-guided fund established by the Suzhou Municipal Government in 2021 with an initial scale of 6 billion yuan. It is one of the leading angel guidance funds of its kind in China. In June 2022, Suzhou Angel FOF, Suzhou Guofa Venture Capital, Suzhou Industrial Investment Group, Suzhou Science and Technology Innovation Investment, and Suzhou Fund were integrated to form the Suzhou Innovation Investment Group. As a member of the SUVC system, Suzhou Angel FOF focuses on the innovative urban development strategy of Suzhou, with investment priorities covering Suzhou's "1030" industrial system (10 key industrial clusters, 30 industrial chains), including strategic emerging industries such as semiconductors, biomedicine, artificial intelligence, and new materials. As of March 2025, Suzhou Angel FOF has invested in nearly 700 enterprises, with a total investment amount close to 10 billion yuan.